Stryker Corporation
SYK
NYSE·Healthcare·Medical - Devices·Mkt cap $116.2B
$303.13
▼ -1.58%
P/E
31.35
Mkt Cap
$116.2B
52-Wk Range
$281.00–$395.90
52-Week Range
$281.00 - $395.90
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 22.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive global distribution network
- Continuous technological innovation
- Comprehensive medical device portfolio
- Strong research and development capabilities
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Aging global population
Value
Fairly valued vs Medical Devices peers
Momentum
Stable
+0.5% over 3m
Quality
Excellent
Strong fundamentals
Dividend
Modest
1.15% yield
Smart-money signal
Who's buying SYK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of $3.69 vs $3.49 consensus (+5.7% surprise). Revenue of $6.6B vs $6.6B expected (+0.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.7%
Revenue trend · last 8Q
—
+11%
+12%
+11%
+10%
+11%
+3%
+9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$5.5B
$6.4B
$5.9B
$6.0B
$6.1B
$7.2B
$6.0B
$6.6B
Margins · last 8Q
Gross
68.3%
Operating
25.2%
Profit
19.4%
Wall Street consensus
15 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: Wolfe Research · Aug 13, 2026
vs Industry
How SYK stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related